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Background:  As time to PCI shortens in Acute Coronary Syndrome (ACS) care, establishing the benefit of novel therapies on ischemic events 
is challenging. We evaluated Cangrelor, an intravenous potent rapid- acting P2Y12 inhibitor in ACS patients undergoing PCI using the Universal 
Definition of MI in an analysis of the CHAMPION trials.
Methods:  The CHAMPION PLATFORM and PCI studies were parallel double-blind phase 3 trials comparing Cangrelor with Clopidogrel in PCI 
patients. Both studies had death, MI or ischemia-driven revascularization (IDR); (including stent thrombosis) at 48 hours as the primary endpoint. 
As the studies had similar inclusion/exclusion criteria, they were pooled. STEMI patients (pre-defined safety population) were excluded as recurrent 
MI could not be discriminated from the index MI. We applied the Universal Definition of MI (Type 4) to the Clinical Events Committee adjudicated MI. 
MI was defined as an elevation of CK-MB > 3x ULN if the baseline was stable/ falling, or new Q-waves. MI re-evaluation was blinded to treatment 
allocation.
Results:  13049 patients were randomized to either Cangrelor or Clopidogrel. The median age was 62.5 years, while females and diabetics were 
28% and 31.7% of the population, respectively. Major (TIMI or GUSTO) bleeding and transfusions were not increased with Cangrelor.
Conclusions:  Using the Universal Definition of MI, Cangrelor was associated with a significant reduction in early ischemic events when compared 
with Clopidogrel in PCI patients.
Cangrelor N=6543 Clopidogrel N=6506 Odds Ratio (95% C.I.) P value
Death/MI Universal Definition/IDR 203/6543 (3.1) 244/6506 (3.8) 0.82 (0.68,0.99) 0.0422
Death 14/6543 (0.2) 23/6506 (0.4) 0.60 (0.31,1.18) 0.1380
MI Universal Definition 172/6543 (2.6) 194/6506 (3.0) 0.88 (0.71,1.08) 0.2222
IDR 32/6543 (0.5) 47/6506 (0.7) 0.68 (0.43,1.06) 0.0878
Stent Thrombosis (ST) 12/6543 (0.2) 27/6506 (0.4) 0.44 (0.22,0.87) 0.0184
Death/MI Universal Definition/(ST) 190/6543 (2.9) 228/6506 (3.5) 0.82 (0.68, 1.00) 0.0517
MI original definition 455/6543 (7.0) 447/6506 (6.9) 1.01 (0.88, 1.16) 0.85100.8510
